GLPwatch
Papers (9189)
Page 137 of 154, ranked by citation count.
- Selective amylin receptor agonism: promise beyond incretins.
- Tirzepatide vs. Semaglutide for Obesity Treatment.
- Drugs for chronic heart failure.
- Obesity in patients without diabetes undergoing coronary artery bypass graft surgery: Time to select patients for semaglutide.
- Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5.
- Real-world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus.
- Design and fabrication of a mesoporous silica scaffold for oral delivery of peptides.
- In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes.
- [Liraglutide for weight loss in overweight and obese adults].
- Effect of ketogenic diet plus dulaglutide on glucose and lipid metabolism in diabetes mellitus.
- Comparison of low-dose liraglutide use versus other GLP-1 receptor agonists in patients without type 2 diabetes.
- GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis.
- Development of a Follow-Up Protocol for Patients Treated with Injectable Semaglutide for Weight Loss: Design of a Research Study in Community Pharmacy.
- GLP-1 RA Medication Associations With Hazardous Alcohol Drinking Reductions in Patients With Overweight or Obesity: A Prospective Observational Study.
- Summary for Patients: Semaglutide or Dulaglutide Versus Empagliflozin for Risk for Death and Cardiovascular Outcomes Among Patients With Type 2 Diabetes.
- CORRECTION: Ozempic v Mounjaro: what is the difference between semaglutide and tirzepatide?
- Correction to: Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
- Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide.
- Effective treatment for fatty liver of liraglutide via inhibiting endoplasmic reticulum stress, oxidative stress and apoptosis pathways.
- Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
- [Pharmacological treatments for obesity : what does the future hold?]
- Two new doses of dulaglutide (Trulicity) for diabetes.
- Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.
- Dulaglutide slows kidney disease in type 2 diabetes - Author's reply.
- Efficacy and Safety of Twincretin Survodutide, a Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist as an Anti-Obesity and Anti-Diabetes Medication: A Systematic Review and Meta-Analysis.
- Correction to "Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes".
- Assessment of the Potential of GLP-1 Analogs in the Treatment of Addictions: A Literature Review.
- Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.
- Comparative effects of pharmacological treatment for weight gain in patients treated with antipsychotics. A systematic review and network meta-analysis.
- Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
- Localized Semaglutide Injection for Hyperinsulinemia-Induced Lymphatic Dysfunction: A Narrative Review Proposing a Promising Metabolic Perspective for Lymphedema Therapy.
- Reducing Periprosthetic Joint Infection in Patients With Obesity: A Systematic Review and Meta-Analysis of the Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists.
- Hormone copycats.
- Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.
- Revitalizing GIP: Therapeutic Potential in Metabolic and Neurodegenerative Disorders.
- Fat, muscle, and anti-obesity medications in cardiovascular disease prevention.
- Impact of GLP-1 RA plus progestin therapy on fertility-sparing management of endometrial intraepithelial neoplasia and endometrial cancer.
- Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie.
- Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder.
- From awareness to action: evolving endocrinologist practices in obesity treatment in Italy.
- [In obese, non-diabetic adults, tirzepatide results in greater weight loss than semaglutide.]
- Healthcare Resource Utilization and Costs in Individuals Who Discontinue Liraglutide and Who Switch from Liraglutide to Once-Weekly Injectable Semaglutide.
- Interventions for prediabetes: an umbrella review of systematic reviews and meta-analyses of randomized controlled trials.
- Efficacy and Safety of Dulaglutide Biosimilar LY05008 Versus the Reference Product Dulaglutide (Trulicity) in Chinese Adults With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Active Comparator Study.
- The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK.
- A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).
- Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center.
- Exenatide Reduces Graft Injury in a Rat Transplantation Model Using Kidneys Donated after Cardiac Death.
- Significant elevation of serum CA19-9 and CA242 levels induced by dulaglutide.
- Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus.
- Management of the T2D Patient With High A1C.
- Expanded table: some available insulins for type 2 diabetes.
- Liraglutide Enhances Cell Viability and Reduces Oxidative Stress in Hyperglycemic H9c2 Cardiomyocytes.
- Lixisenatide for type 2 diabetes.
- Innovative Glucagon-like Peptide 1 Receptor Agonists: Exploring the Therapeutic Potential of Specific Modified Monomer, Dimer, and Tetramer in Type 2 Diabetes Treatment.
- Positron emission tomography to assess drug occupancy at peripheral and central incretin receptors.
- GLP-1 Receptor Agonist Use and Wound Outcomes After Free Flap Breast Reconstruction.
- Tirzepatide reduces intracellular lipid content by promoting the browning of white fat via the cAMP signaling pathway.
- Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.
- [Type 2 diabetes. Lixisenatide - effective in combination].